405 related articles for article (PubMed ID: 28676669)
21. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
[TBL] [Abstract][Full Text] [Related]
22. Carfilzomib.
Engelhardt M; Szymaniak-Vits M; Ajayi S; Dold SM; Müller SJ; Scheubeck S; Wäsch R
Recent Results Cancer Res; 2018; 212():265-283. PubMed ID: 30069635
[TBL] [Abstract][Full Text] [Related]
23. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
[TBL] [Abstract][Full Text] [Related]
24. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
25. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Gu Y; Wang X; Wang Y; Wang Y; Li J; Yu FX
Cell Signal; 2020 Nov; 75():109775. PubMed ID: 32916277
[TBL] [Abstract][Full Text] [Related]
26. Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.
Muz B; Kusdono HD; Azab F; de la Puente P; Federico C; Fiala M; Vij R; Salama NN; Azab AK
Leuk Lymphoma; 2017 Dec; 58(12):2916-2925. PubMed ID: 28509582
[TBL] [Abstract][Full Text] [Related]
27. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
28. RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway.
Wang Q; Lin Z; Wang Z; Ye L; Xian M; Xiao L; Su P; Bi E; Huang YH; Qian J; Liu L; Ma X; Yang M; Xiong W; Zu Y; Pingali SR; Xu B; Yi Q
Blood; 2022 Jan; 139(1):59-72. PubMed ID: 34411225
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
30. Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.
Chong KY; Hsu CJ; Hung TH; Hu HS; Huang TT; Wang TH; Wang C; Chen CM; Choo KB; Tseng CP
Cancer Biol Ther; 2015; 16(1):149-59. PubMed ID: 25590413
[TBL] [Abstract][Full Text] [Related]
31. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
[TBL] [Abstract][Full Text] [Related]
32. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
[TBL] [Abstract][Full Text] [Related]
33. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
34. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
[TBL] [Abstract][Full Text] [Related]
35. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
36. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
[TBL] [Abstract][Full Text] [Related]
37. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
38. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
40. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]